Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium
Van Hauwermeiren, Filip × Armaka, Marietta Karagianni, Niki Kranidioti, Ksanthi Vandenbroucke, Roosmarijn E Loges, Sonja Van Roy, Maarten Staelens, Jan Puimège, Leen Palagani, Ajay Berghe, Wim Vanden Victoratos, Panayiotis Carmeliet, Peter Libert, Claude Kollias, George #
American Society for Clinical Investigation
Journal of Clinical Investigation vol:123 issue:6 pages:2590-2603
TNF has remarkable antitumor activities; however, therapeutic applications have not been possible because of the systemic and lethal proinflammatory effects induced by TNF. Both the antitumor and inflammatory effects of TNF are mediated by the TNF receptor p55 (p55TNFR) (encoded by the Tnfrsf1a gene). The antitumor effect stems from an induction of cell death in tumor endothelium, but the cell type that initiates the lethal inflammatory cascade has been unclear. Using conditional Tnfrsf1a knockout or reactivation mice, we found that the expression level of p55TNFR in intestinal epithelial cells (IECs) is a crucial determinant in TNF-induced lethal inflammation. Remarkably, tumor endothelium and IECs exhibited differential sensitivities to TNF when p55TNFR levels were reduced. Tumor-bearing Tnfrsf1a+/- or IEC-specific p55TNFR-deficient mice showed resistance to TNF-induced lethality, while the tumor endothelium remained fully responsive to TNF-induced apoptosis and tumors regressed. We demonstrate proof of principle for clinical application of this approach using neutralizing anti-human p55TNFR antibodies in human TNFRSF1A knockin mice. Our results uncover an important cellular basis of TNF toxicity and reveal that IEC-specific or systemic reduction of p55TNFR mitigates TNF toxicity without loss of antitumor efficacy.